Cite
HARVARD Citation
Ulahannan, S. et al. (n.d.). A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage. European journal of cancer. pp. S92-S93. [Online].